Tesofensine

CAT: 0804-HY-14472-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-14472-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE; IC50=1.7 nM), and serotonin (5-HT; IC50=11 nM), and with potentials as an anti-obesity agent[1]. Tesofensine is a CNS acting anti-obesity agent[2].
CAS Number
[195875-84-4]
Product Name Alternative
NS-2330
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Dopamine Transporter; Serotonin Transporter
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/tesofensine.html
Purity
99.31
Solubility
DMSO : 2 mg/mL (ultrasonic; warming)
Smiles
CN1[C@@]2([H])[C@H](COCC)[C@@H](C3=CC=C(Cl)C(Cl)=C3)C[C@]1([H])CC2
Molecular Formula
C17H23Cl2NO
Molecular Weight
328.28
Precautions
H315, H319, H335
References & Citations
[1]Lieuwe Appel, et al. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2014 Feb;24 (2) :251-61.|[2]Ann A Coulter, et al. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018 Jul;78 (11) :1113-1132.|[3]Anne Marie D Axel, et al. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.Neuropsychopharmacology. 2010 Jun;35 (7) :1464-76.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

Popular Products